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Abstract
Summary A country-specific FRAX® model was developed
from the epidemiology of fracture and death in Belgium.
Fracture probabilities were identified that corresponded to
currently accepted reimbursement thresholds.
Introduction The objective of this study was to evaluate a
Belgian version of the WHO fracture risk assessment
(FRAX®) tool to compute 10-year probabilities of osteopo-
rotic fracture in men and women. A particular aim was to
determine fracture probabilities that corresponded to the
reimbursement policy for the management of osteoporosis in
Belgium and the clinical scenarios that gave equivalent
fracture probabilities.
Methods Fracture probabilities were computed from pub-
lished data on the fracture and death hazards in Belgium.
Probabilities took account of age, sex, the presence of clinical
risk factors and femoral neck bone mineral density (BMD).
Fracture probabilities were determined that were equivalent to
intervention (reimbursement) thresholds currently used in
Belgium.
Results Fracture probability increased with age, lower BMI,
decreasing BMD T-score and all clinical risk factors used
alone or combined. The 10-year probabilities of a major
osteoporosis-related fracture that corresponded to current
reimbursement guidelines ranged from approximately 7.5%
at the age of 50 years to 26% at the age of 80 years where a
prior fragility fracture was used as an intervention threshold.
For women at the threshold of osteoporosis (femoral neck
T-score=−2.5 SD), the respective probabilities ranged from
7.4% to 15%. Several combinations of risk-factor profiles
were identified that gave similar or higher fracture probabil-
ities than those currently accepted for reimbursement in
Belgium.
Conclusions The FRAX® tool has been used to identify
possible thresholds for therapeutic intervention in Belgium,
based on equivalence of risk with current guidelines. The
FRAX® model supports a shift from the current DXA-
based intervention strategy, towards a strategy based on
fracture probability of a major osteoporotic fracture that in
turn may improve identification of patients at increased
fracture risk. The approach will need to be supported by
health economic analyses.
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Introduction
The diagnosis of osteoporosis is based on the measurement of
bone mineral density (BMD) by dual X-ray absorptiometry
(DXA). The World Health Organization has provided an
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operational definition of osteoporosis given as a BMD that lies
2.5 standard deviations (SDs) or more below the average
mean value of young healthy women (T-score≤−2.5 SD) [1].
More recently, a standardised reference site (the femoral
neck) and a standard reference range (the NHANES III
data for women aged 20–29 years) [2] has been provided
[3]. The operational definition of osteoporosis has been
adopted by many agencies as one of the criteria for
treatment [4–7].
Although low BMD is a major risk factor for fracture,
many prospective studies have shown that, although
fracture risk increases with decreasing BMD, most
fractures occur in subjects with a BMD T-score above
the operational threshold [8–10]. Recently, the use of
clinical risk factors (CRFs) has been shown to enhance the
performance of BMD in the prediction of hip and
osteoporotic fractures in men and women [11]. In order
to identify the CRFs for osteoporotic fracture, data were
analysed from nine prospective primary cohorts and 11
prospective validation cohorts, including more than
275,000 persons corresponding to 1.4 million person-
years with more than 22,711 reported fractures [11]. In
addition to a prior fragility fracture, age, sex body mass
index and additional risk factors for fractures were
identified including the prior use of glucocorticoids,
secondary osteoporosis, rheumatoid arthritis, a parental
history of hip fracture, current cigarette smoking and
alcohol intake of three or more units per day.
These analyses form the basis for the development of
FRAX®, a computer-based algorithm (http://www.shef.
ac.uk/FRAX) that provides models for assessment of
fracture probability in men and women from the informa-
tion provided from the CRFs [5, 12]. The 10-year fracture
probability can be derived from the CRFs alone or with
femoral neck BMD to enhance fracture risk prediction. In
addition to the clinical risk factors, fracture probability
varies markedly in different regions of the world [13].
Thus, the FRAX® models need to be calibrated to those
regions where the epidemiology of fracture and death is
known. At present, FRAX® models are available for
Argentina, Austria, Belgium, China, Finland, France,
Germany, Hong Kong, Italy, Japan, Lebanon, New
Zealand, Spain, Sweden, Switzerland, Turkey, the UK
and USA [12, 14–16], and several others are being
developed.
In an earlier publication, the elements required to populate
a Belgian-specific FRAX® model were reported [17]. The
aim of this study was to describe a fracture probability model
for Belgium. Given the current recommendations for
treatment in Belgium, an additional aim was to determine
which clinical risk factors, alone or in combination, and with
or without a BMD measurement, might qualify for treatment
in a Belgian environment.
Methods
Models were constructed to compute the 10-year probability
of hip fracture and a major osteoporosis-related fracture
in Belgium using the methodology previously described
for the development of the FRAX® in the UK [12]. A
major osteoporosis-related fracture was defined as a
clinical spine, hip, proximal humeral or forearm fracture.
Poisson models were used to calculate the hazard
functions of fracture and death. The relationship between
the hazard functions was used to calculate the 10-year
probability or fracture for a combination of given risk
factors. The mortality estimates for Belgium were those
published by the World Health Organization for 1999 [18].
The incidence of hip fracture was taken from a previously
published source [17]. Since the incidence of other
fractures was not known in Belgium, we assumed that
the age- and sex-specific ratio of index fracture to hip
fracture in Belgium was the same as found in Sweden.
This assumption, used in the development of several
FRAX® models [5], appears to hold true for West
European countries, the USA and Australia [19].
The relationship of clinical risk factors to fracture
outcomes was assumed to be the same as that
determined in a large meta-analysis of risk factors
derived from prospectively studied population-based
cohorts from Europe, Australia, North America and
Asia. The independent contribution of each risk factor
was used to compute probabilities of fracture in the
absence of clinical risk factors or in the presence of
any combination [11].
In Belgium, access to reimbursable treatment depends
on the intervention envisaged and is largely predicated
by price. Generic alendronate has no restriction for
reimbursement in men and women. For branded
bisphosphonates and raloxifene (in women), patients
with a prior vertebral fracture and/or a T-score of less
than −2.5 SD at the lumbar spine, total hip or femoral
neck qualify for reimbursement using the Belgian
normative reference ranges [20, 21]. For strontium
ranelate, the same criteria are applied to women aged
80 years or older. More stringent criteria are applied to
teriparatide in women. For the purposes of this report,
we assessed fracture probabilities that were equivalent
to a prior fragility fracture or a T-score of −2.5 SD for
BMD at the femoral neck. The T-score was computed
using the NHANES III as a reference for BMD at the
femoral neck in Caucasian women aged 20–29 years
[2]. The calculation of fracture probability was made at a
body mass index (BMI) of 25 kg/m2 unless otherwise
stated. Changes in BMI have little effect on predictive
value for fracture risk assessment in the presence of BMD
[22].
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Results
Clinical risk factors
The contribution of clinical risk factors to fracture
probability is shown in Table 1 for men and women with
a BMI of 25 kg/m2. In women without clinical risk factors,
the 10-year probability for an osteoporosis-related fracture
was 3.4% at the age of 50 years and rose with age to 19% at
the age of 90 years. The 10-year probability was higher in
the presence of clinical risk factors. Smoking and alcohol
were relatively weak risk factors; the use of long-term
glucocorticoids of intermediate weight and a parental
history of hip fracture or a prior fragility fracture were
associated with the highest risks. At the age of 70 years for
example, the 10-year probability was 11% for smokers and
18% for women with a prior fracture. Probabilities were
consistently lower in men than in women.
BMD
The 10-year probability of a major osteoporotic fracture for
women without clinical risk factors is shown in Fig. 1
grouped by age and T-score. In women, the 10-year
probability of fracture increased with age and with
decreasing T-score up to the age of 80 years and then
declined in women with the lower T-scores because of the
competing effect of the death risk on fracture probability.
At younger ages, the fracture probability was similar in
men and women. For example, at the age of 50 years with a
T-score of 1.0 SD, the probability of a major fracture was
2.4% in men and 2.9% in women. With advancing age,
probabilities in men rose as expected at high T-scores, but
decreased above the age of 80 years. At the extreme of T-
score (−4.0 SD), probabilities decreased progressively with
age because of the more marked competing effect of the
death risk on fracture probability.
Intervention thresholds
Table 2 shows the fracture probabilities in women equiv-
alent to the two thresholds for the reimbursement of
treatments in Belgium. Thus, the levels of probability were
equivalent either to a BMD set at a T-score of −2.5 SD in
women without a previous fracture or to that in women
with a previous fragility fracture. These probabilities are
compared with women with no clinical risk factors in the
absence of BMD (Table 2).
In women aged 50, 60, 70 and 80 years without
clinical risk factors and with a BMD T-score of
−2.5 SD, the 10-year probability of a major osteoporotic
fracture was 6.7%, 9.3%, 13% and 15%, respectively. In
women with no CRFs and no BMD tests, the equivalent
probabilities were 3.4%, 5.7%, 9.6% and 16%, respec-
tively. Thus, the BMD criterion for reimbursement using
a fixed T-score became less and less appropriate with
advancing age. For example, at the age of 50 years,
women with a T-score of −2.5 SD had a two-fold
higher probability than women of the same age and no
CRFs. In contrast, at the age of 80 years and older,
fracture probabilities were lower in women at the
threshold of osteoporosis than their counterparts with
no risk factors. The phenomenon was even more
marked when hip fracture probabilities were considered
(see Table 2). The situation arises because of the decrease
in T-score that occurs with advancing age. Indeed, the
average T-score at the age of 80 years is <−2.5 SD, so that
a woman with a T-score of −2.5 SD has a higher-than-
average T-score.
In women with a previous fracture, probabilities were
consistently greater than in women at the threshold of
osteoporosis and rose progressively with age up to the age
of 85 years. This suggests that the probabilities equivalent
to a prior fracture might be considered as a reference value
above which patients could receive reimbursement for
treatment in the absence of a prior fracture as indicated in
Fig. 2.
Table 1 10-year probability of a major fracture (%) in men and
women according to the presence of clinical risk factors (CRFs) in the
absence of BMD
CRFs Age (years)
50 60 70 80 90
Men
None 2.7 3.7 5.1 6.7 7.6
Alcohol 3.3 4.5 6.4 8.9 10
Rheumatoid arthritis 3.7 5.1 7.3 10 12
Glucocorticoids 4.4 5.9 7.9 9.7 11
Smoking 2.8 3.9 5.5 7.2 8.1
Parental history 5.4 7.1 8.4 15 17
Prior fracture 5.8 7.6 9.6 11 12
BMI at 20 kg/m2a 2.8 3.9 5.5 7.2 8.0
Women
None 3.4 5.7 9.6 16 19
Alcohol 4.1 6.9 12 21 25
Rheumatoid arthritis 4.7 7.8 14 23 27
Glucocorticoids 5.6 9.4 16 25 26
Smoking 3.6 6.2 11 18 20
Parental history 6.8 11 16 31 35
Prior fracture 7.4 12 18 26 30
BMI at 20 kg/m2a 3.6 6.3 11 19 20
BMI is set at 25 kg/m2 except where indicated
a No other CRF
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Multiple clinical risk factors
Each of the CRFs had an additive effect on fracture
probability. For example, at the age of 65 years, the 10-year
probability of hip fracture was 1.5% in the absence of CRFs
with a BMI set at 25 kg/m2 (see Table 2). In the presence of
one risk factor, this ranged from 2.0–3.7% depending on the
weight of the risk factor. The mean and range increased
progressively according to the number of CRFs, so that with
four CRFs, the hip fracture probability ranged from 7.7–19%
with a mean of 13%. Further examples are given in Fig. 3.
Figure 3 also shows the effect of multiple risk factors in
women of the same age at the threshold of osteoporosis.
Mean hip fracture probabilities rose from 3.5% to 17%,
depending on the number of CRFs.
As expected, probabilities of a major osteoporotic
fracture also rose with increasing numbers of CRFs and
ranged from 7.4% with no CRF to 54% with a combination
of the four strongest risk factors (Fig. 3). The 10-year
probability of a major fracture in women aged 65 years
with a prior fracture was 15%. If this is taken as a
reimbursement or treatment threshold, then, this threshold
is exceeded in several scenarios of combinations. Indeed,
with three or more CRFs, all possible combinations gave a
fracture probability of 15% or more. A comparable effect
was seen in the case of hip fracture probabilities using a
threshold of 3.7%.
Examples of risk-factor pairs are given in Table 3 for
women at the age of 60 and 80 years. At the age of
60 years, the reimbursement threshold was 12% for a major
fracture. Several pairs of risk factors exceeded this
threshold, despite no information on BMD. The threshold
at the age of 80 years (26%) was exceeded in the majority
of combinations.
In the presence of BMD, the intervention threshold was
exceeded in women with no CRFs and a T-score of less
Table 2 10-year probabilities of a major osteoporotic fracture (hip, clinical spine, humerus and forearm) and a hip fracture calculated with the
Belgium FRAX® model
Age (years)
50 55 60 65 70 75 80 85 90
Major osteoporotic fracture
Previous fracturea 7.4 9.9 12 15 18 20 26 31 30
BMD T-score –2.5 SDa 6.7 8.6 9.3 11 13 13 15 16 14
Previous fracture + BMD T-score –2.5 SD 13 15 16 18 20 20 21 23 20
No clinical risk factors 3.4 4.7 5.7 7.4 9.6 12 16 20 19
Hip fracture
Previous fracturea 1.1 1.8 2.4 3.7 5.7 8.4 11 14 14
BMD T-score –2.5 SDa 2.1 2.8 2.9 3.5 4.4 5.6 6.7 6.7 5.8
Previous fracture + BMD T-score –2.5 SD 4.5 5.3 5.2 5.8 6.8 7.9 8.7 8.8 7.6
No clinical risk factors 0.3 0.5 0.8 1.5 2.7 4.7 7.4 9.3 9.4
The table shows the result for women with BMI of 25 kg/m2
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Fig. 1 10-year probabilities of a
major osteoporotic fracture (%)
in men and women according to
the T-score of BMD at the
femoral neck. Individuals are
assumed to have no clinical
risk factors and BMI is set at
25 kg/m2 [09Ca121]
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than −2.9, −3.1, −3.5 and −4.2 SD at the ages of 60, 70, 80
and 90 years, respectively.
Discussion
The present study describes the FRAX® model for the
assessment of fracture probability in men and women from
Belgium. The model has been calibrated to the epidemiology
of hip fracture that has recently been characterised for
Belgium and has been recently added to the FRAX Web site
(version 3.0; http://www.shef.ac.uk/FRAX/index.htm).
The strengths and limitations of FRAX have been
extensively reported [5, 23], but the technology permits
an estimate of fracture probability that integrates in a
quantitative manner the information from multiple risk
factors, with or without information on BMD. The
inclusion of the risk factors improves the performance of
assessment by increasing sensitivity (detection rate of who
will fracture) without sacrificing specificity [11, 24].
Several previous studies have developed models to
predict fracture risk from the combination of clinical risk
factors and BMD [25–40]. The risk factors used include
activities of daily living, impaired cognition, liability to
falls, poor overall health, history of stroke, seizure
disorder and several different medications. A limitation
of many of these studies is that they have not been
extensively tested in other cohorts. The model described
in this paper has been validated in 11 independent
prospectively studied cohorts with in excess of 1 million
patient years [11]. Moreover, most other risk engines have
not incorporated mortality, or incompletely so, and have
not considered whether the risk factors used identify a risk
that is reversible with intervention.
Many lines of evidence [41, 42] suggest that the FRAX®
algorithms identify individuals in whom a high risk is
responsive to pharmacological interventions. To test the
hypothesis directly that a candidate risk factor identified a
risk amenable to treatment, it would be necessary to recruit
individuals selected on the basis of the risk factor(s) to a
randomised controlled trial (RCT). The risk factor that is
best evaluated in this way is BMD; and indeed the majority
of therapeutic studies have recruited on the basis of low
BMD as recommended by regulatory agencies in Europe
[43]. In recent years, other trials have recruited on the basis
of age, gender, a prior vertebral fracture and current
exposure to glucocorticoids irrespective of BMD, and have
shown therapeutic effects similar to those noted in RCTs
based on BMD selection [44–46].
For other individual risk factors, comparable data are
lacking, but several considerations suggest that the choice
of these risk factors is appropriate in the context of
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Fig. 3 10-year probability of hip fracture (%) in women aged 65 years
according to the number of clinical risk factors. The left-hand panel
shows the probabilities without BMD at a BMI fixed at 25 kg/m2. The
right-hand panel illustrates the effects with BMD fixed at the threshold
for osteoporosis. The bars indicate the mean value and the vertical lines
denote the range of probabilities dependent on the weight of the risk
factors [09Ca124]



































Fig. 2 10-year probability (%)
of a major fracture (left panel) or
a hip fracture (right) in women
from Belgium with a prior
fracture but no other clinical risk
factors. BMI is set at 25 kg/m2
[09Ca122]
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shown that intervention in the general population induces
therapeutic results similar to those expected in individuals
selected to be at high risk [47–49]. Second, studies have
shown no significant interaction between response to
treatment and the presence or absence of the risk factors
used in the present study including age, height, family
history of fracture, low body weight or BMI, smoking,
alcohol intake or prior non-vertebral fracture [50–54].
Third, the clinical risk factors are not totally independent
of BMD, and when clinical risk factors alone are used in
women aged 70 years or more, BMD is approximately
1 SD lower in the high-risk group compared with a low-risk
group [55]. Perhaps, the best evidence is that response to
intervention in elderly women recruited from the general
population is greater, the higher the probability of fracture
estimated without the inclusion of BMD in FRAX® [56].
Similar findings are reported for the SERM bazedoxifene. In
this phase III intervention study, relative risk reduction
compared with placebo was greater in women with the higher
baseline fracture probabilities [57]. These considerations
suggest that the risk factors chosen are appropriate in that
they identify a risk that is amenable to pharmacological
intervention.
Any clinical utility of FRAX® will be dependent on the
manner by which probabilities are used to make clinical
decisions on the management of patients. Practice guidelines
or reimbursement criteria have been traditionally based on
BMD thresholds [4–7]. However, the majority of fractures
occur in individuals who would be considered to be at low
risk on the basis of BMD alone [8–10]. If, for example, if it
was considered appropriate to identify women in Sweden at
the age of 65 years in the highest decile of risk, then 75% of
all hip fractures would occur in those women categorised as
being at low risk with a test with a gradient of fracture risk of
2.0 [10].
In this paper, we have explored a “translational approach”
to guideline development by examining existing guidance and
converting thresholds to fracture probabilities. The threshold
chosen corresponds to a woman with a prior fragility fracture
with an average BMD. This threshold will be marginally
lower than the probability of the population with a prior
fracture since a small segment of the population will have
other FRAX® risk factors [41]. With this caveat, the present
study shows that 10-year fracture probabilities equivalent to
those currently accepted for reimbursement of treatment in
Belgium are achieved with several clinical risk factor profiles
and combinations. These include risk factors not (yet)
accepted for reimbursement, such as a parental history of
fracture, tobacco and/or alcohol abuse and rheumatoid
arthritis. Thus, treatment is not equally accessible to all
patients presenting with identical fracture risks. In this
context, FRAX® represents a unique opportunity for
identifying additional individuals who can benefit from
treatment. FRAX® may also assist in identifying individuals
















Women aged 60 years
No clinical risk factors 5.7
Current cigarette smoking 6.2
Alcohol intake≥3 units daily 7.7 6.9
Rheumatoid arthritis 8.6 9.6 7.8
Oral glucocorticoids 10 12 13 9.4
Previous fragility fracture 12a 13 14 16 19 12
Parental history of hip fracture 11 13 15 17 21 11
Women aged 80 years
No clinical risk factors 16
Current cigarette smoking 18
Alcohol intake≥3 units daily 24 11
Rheumatoid arthritis 27 30 23
Oral glucocorticoids 28 32 35 14
Previous fragility fracture 26a 28 32 35 37 26
Parental history of hip fracture 37 40 44 46 44 31
Rows in italics indicate probabilities associated with a prior fracture and currently accepted for reimbursement in Belgium. Equal or higher
probabilities are shown in bold font
a Indicate the fracture probability associated with a prior fracture and no other clinical risk factors
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at low risk but who would be eligible for treatment under
existing arrangements. An example is provided in the
present study in the use of BMD alone as a treatment
threshold. If, for the sake of argument, it was considered
appropriate to use the intervention threshold suggested in
the present study, as has been recommended in several
countries [15, 16, 58, 59], then, intervention would be
recommended at the probabilities shown in Fig. 2. Under
this scheme, women at the age of 55 years with a T-score
of −2.5 SD and no clinical risk factors would have a
fracture probability of 8.6% (see Table 2) which is close to
the intervention threshold of 9.9%. By contrast, a woman
at the age of 80 years with the same T-score would have a
fracture probability (15%) very much lower than the
intervention threshold (26%). Indeed, in this example,
the fracture probability (15%) is similar to that of the
general population of women at that age (16% without any
CRFs). The reason is that the T-score diminishes with age
so that at the age of 55 years, this T-score affords a
substantial risk compared with women with an average T-
score of the same age. At the age of 80 years, a T-score of
−2.5 SD is higher than the average T-score for that age.
Thus, the use of FRAX® can aid both in targeting
treatments to individuals at high risk and by excluding
individuals who would otherwise have received an
inappropriate treatment. Both measures will improve the
cost-effectiveness of case-finding.
We conclude that the FRAX® tool can be used to identify
possible thresholds for therapeutic intervention in Belgium,
based on equivalence of risk with current guidelines. The
FRAX® model supports a shift from the current DXA-based
intervention strategy, towards a strategy based on fracture
probability of a major osteoporotic fracture that in turn may
improve identification of patients at increased fracture risk.
The approach will need to be supported by health economic
analyses.
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